Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ранние прогностические маркеры преэклампсии
Ранние прогностические маркеры преэклампсии
Дубровина С.О., Муцалханова Ю.С. Ранние прогностические маркеры преэклампсии. Гинекология. 2016; 18 (5): 38–43.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Несмотря на то что преэклампсия считается лидирующей причиной перинатальной заболеваемости и смертности, ее патофизиология остается неизвестной. Ранний прогноз преэклампсии позволит вовремя начать превентивную терапию. Сочетание анамнеза, биофизических и биохимических маркеров предпочтительнее других тестов в раннем прогнозировании развития преэклампсии. В данной статье проанализированы недавние исследования наиболее важных стратегий по прогнозу преэклампсии, включая материнские факторы риска и биомаркеры.
Ключевые слова: преэклампсия, беременность, биомаркеры, прогноз.
Key words: preeclampsia, pregnancy, biomarker, prognosis.
Ключевые слова: преэклампсия, беременность, биомаркеры, прогноз.
________________________________________________
Key words: preeclampsia, pregnancy, biomarker, prognosis.
Полный текст
Список литературы
1. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am SocNephrol 2007; 2: 543–9.
2. Ghulmiyyah, L, Sibai, B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36: 56–9.
3. Ananth CV, Keyes KM, Wapner RJ. Preeclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ 2013; 347: f6564.
4. Yliniemi A, Nurkkala M-M, Kopman S, Korpimaki T et al. First Trimester Placental Retinol-Binding Protein 4 (RBP4) and Pregnancy-Associated Placental Protein A (PAPP-A) in the Prediction of Early-Onset Severe Preeclampsia. Metabol clinic experimental 2015; 64: 521–26.
5. Somani S, Choudhary V, Babu P, Vijayalaxmi A. To determine association of lipid profile, serum uric acid and body mass index as a marker for preeclampsia. Int J Cur Res Rev 2015; 7 (11): 53–7.
6. North RA, McCowan LM, Dekker GA et al. Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort. BMJ 2011; 342. doi:10.1136/ bmj.d1875.
7. Wu P, van den Berg C, Alfirevic Z, O’Brien S et al. Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. Int J Mol Sci 2015; 16: 23035–56.
8. Thilaganathan B, Wormald B, Zanardini C et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 1233–8.
9. Roberge S, Giguere Y, Villa P et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012; 29: 551–6 [PubMed: 22495898].
10. Akolekar R, Syngelaki A, Sarquis R et al. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 66–74.
11. Koopmans CM, Bijlenga D, Groen H et al. Induction of labour vs. expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): A multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979–88.
12. Yu CK, Khouri O, Onwudiwe N et al. Medicine Foundation Second-Trimester Screening Group. Prediction of preeclampsia by uterine artery Doppler imaging: Relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310–3.
13. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. Int J Mol Sci 2015; 16: 17952–74.
14. Anderson UD, Gram M, Thilaganathan B et al. [97-POS]: Free fetal hemoglobin and hemoglobin-scavenging proteins are predictive first and second trimester biochemical markers for preeclampsia. Pregnancy Hypertens 2015; 5: 53.
15. Small H, Currie G, Delles C. Prostasin, proteases, and preeclampsia. J Hypertens 2016; 34: 193–5.
16. Allen RE, Rogozinska E, Cleverly K et al. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 182: 194–201. doi: 10.1016/j.ejogrb.2014.09.027 PMID: 25305662.
17. Garcé́s M, Sanchez E, Cardona L, Simanca E et al. Maternal serum meteorin levels and the risk of preeclampsia. PLoS One. doi: 10.1371/journal.pone.0131013.
18. Cuckle HS. Screening for preeclampsia – Lessons from aneuploidy screening. Placent 2011; 32 (Suppl. 1): S42–S48.
19. Redman CWG, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24: 565–70.
20. Tangerå̊s L, Austdal M, Skrå̊̊stad R, Salvesen K et al. Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia. Arterioscler Thromb Vasc Biol 2015; 35: 2478–85.
21. Tsiakkas A, Duvdevani N, Wright A et al. Serum placental growth factor in the three trimesters of pregnancy: Effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 591–8.
22. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–83.
23. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor [IGF]- dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149–53.
24. Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37–45.
25. Bersinger NA, Smarason AK, Muttukrishna S et al. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin-A, activin-A and soluble E-selectin. Hypertens Pregnancy 2003; 22: 45–55.
26. Poon LC, Akolekar R, Lachmann R et al. Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010; 35: 662–70.
27. Sibai BM, Koch MA, Freire S et al. Serum inhibin-A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: Are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008; 199: 268e1–e9.
28. Shi Z, Xu W, Loechel F et al. ADAM 12, a disintegrinmetalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574–80.
29. Loechel F, Fox JW, Murphy G et al. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511–5.
30. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212–6.
31. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod 2007; 13: 189–95.
32. Thilaganathan B, Ralph E, Papageorghiou AT et al. Raised maternal serum cystatin C: An early pregnancy marker for preeclampsia. Reprod Sci 2009; 16: 788–93.
33. Metcalfe A, Langlois S, Macfarlane J et al. Prediction of obstetrical risk using maternal serum markers and clinical risk factors. Prenat Diagn 2013; 2: 172–9.
34. Vaisbuch E, Romero R, Mazaki-Tovi S et al. Retinol binding protein 4 – a novel association with early-onset preeclampsia. J Perinat Med 2010; 382: 129–39.
35. Alkharfy KM, Al-Daghri NM, Vanhoutte PM et al. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS One 2012; 710: e48612.
36. Shangguan XI, Liu F, Wang H et al. Alterations in serum adipocyte fatty acid binding protein and retinol binding protein-4 in normal pregnancy and preeclampsia. Clin Chim Acta 2009; 4071–2: 58–61.
37. Myatt L, Clifton RG, Roberts JM et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] Maternal-Fetal Medicine Units [MFMU] Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 1196: 1234–42.
38. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
39. Stepan H, Ebert T, Schrey S et al. Preliminary report: serum levels of retinol binding protein 4 in preeclampsia. Metab Clin Exp 2009; 58: 275–7.
40. Nanda S, Nikoletakis G, Markova D et al. Maternal serum retinol-binding protein-4 at 11–13 weeks' gestation in normal and pathological pregnancies. Metabolism 2013; 626: 814–9.
41. Giguere Y, Masse J, Theriault S et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG 2015; 122: 402–10.
42. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
43. Powers RW, Roberts JM, Plymire DA et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 2012; 60: 239–46.
44. Дубровина С.О., Муцалханова Ю.С., Тикиджиева В.Ю. Поиск ранних прогностических маркеров преэклампсии. Таврический медико-биологич. вестн. 2016; 19 (2): 62–4. / Dubrovina S.O., Mutsalkhanova Iu.S., Tikidzhieva V.Iu. Poisk rannikh prognosticheskikh markerov preeklampsii. Tavricheskii mediko-biologich. vestn. 2016; 19 (2): 62–4. [in Russian]
2. Ghulmiyyah, L, Sibai, B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36: 56–9.
3. Ananth CV, Keyes KM, Wapner RJ. Preeclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ 2013; 347: f6564.
4. Yliniemi A, Nurkkala M-M, Kopman S, Korpimaki T et al. First Trimester Placental Retinol-Binding Protein 4 (RBP4) and Pregnancy-Associated Placental Protein A (PAPP-A) in the Prediction of Early-Onset Severe Preeclampsia. Metabol clinic experimental 2015; 64: 521–26.
5. Somani S, Choudhary V, Babu P, Vijayalaxmi A. To determine association of lipid profile, serum uric acid and body mass index as a marker for preeclampsia. Int J Cur Res Rev 2015; 7 (11): 53–7.
6. North RA, McCowan LM, Dekker GA et al. Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort. BMJ 2011; 342. doi:10.1136/ bmj.d1875.
7. Wu P, van den Berg C, Alfirevic Z, O’Brien S et al. Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. Int J Mol Sci 2015; 16: 23035–56.
8. Thilaganathan B, Wormald B, Zanardini C et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 1233–8.
9. Roberge S, Giguere Y, Villa P et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012; 29: 551–6 [PubMed: 22495898].
10. Akolekar R, Syngelaki A, Sarquis R et al. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 66–74.
11. Koopmans CM, Bijlenga D, Groen H et al. Induction of labour vs. expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): A multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979–88.
12. Yu CK, Khouri O, Onwudiwe N et al. Medicine Foundation Second-Trimester Screening Group. Prediction of preeclampsia by uterine artery Doppler imaging: Relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310–3.
13. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. Int J Mol Sci 2015; 16: 17952–74.
14. Anderson UD, Gram M, Thilaganathan B et al. [97-POS]: Free fetal hemoglobin and hemoglobin-scavenging proteins are predictive first and second trimester biochemical markers for preeclampsia. Pregnancy Hypertens 2015; 5: 53.
15. Small H, Currie G, Delles C. Prostasin, proteases, and preeclampsia. J Hypertens 2016; 34: 193–5.
16. Allen RE, Rogozinska E, Cleverly K et al. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 182: 194–201. doi: 10.1016/j.ejogrb.2014.09.027 PMID: 25305662.
17. Garcé́s M, Sanchez E, Cardona L, Simanca E et al. Maternal serum meteorin levels and the risk of preeclampsia. PLoS One. doi: 10.1371/journal.pone.0131013.
18. Cuckle HS. Screening for preeclampsia – Lessons from aneuploidy screening. Placent 2011; 32 (Suppl. 1): S42–S48.
19. Redman CWG, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24: 565–70.
20. Tangerå̊s L, Austdal M, Skrå̊̊stad R, Salvesen K et al. Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia. Arterioscler Thromb Vasc Biol 2015; 35: 2478–85.
21. Tsiakkas A, Duvdevani N, Wright A et al. Serum placental growth factor in the three trimesters of pregnancy: Effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 591–8.
22. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–83.
23. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor [IGF]- dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149–53.
24. Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37–45.
25. Bersinger NA, Smarason AK, Muttukrishna S et al. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin-A, activin-A and soluble E-selectin. Hypertens Pregnancy 2003; 22: 45–55.
26. Poon LC, Akolekar R, Lachmann R et al. Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010; 35: 662–70.
27. Sibai BM, Koch MA, Freire S et al. Serum inhibin-A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: Are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008; 199: 268e1–e9.
28. Shi Z, Xu W, Loechel F et al. ADAM 12, a disintegrinmetalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574–80.
29. Loechel F, Fox JW, Murphy G et al. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511–5.
30. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212–6.
31. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod 2007; 13: 189–95.
32. Thilaganathan B, Ralph E, Papageorghiou AT et al. Raised maternal serum cystatin C: An early pregnancy marker for preeclampsia. Reprod Sci 2009; 16: 788–93.
33. Metcalfe A, Langlois S, Macfarlane J et al. Prediction of obstetrical risk using maternal serum markers and clinical risk factors. Prenat Diagn 2013; 2: 172–9.
34. Vaisbuch E, Romero R, Mazaki-Tovi S et al. Retinol binding protein 4 – a novel association with early-onset preeclampsia. J Perinat Med 2010; 382: 129–39.
35. Alkharfy KM, Al-Daghri NM, Vanhoutte PM et al. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS One 2012; 710: e48612.
36. Shangguan XI, Liu F, Wang H et al. Alterations in serum adipocyte fatty acid binding protein and retinol binding protein-4 in normal pregnancy and preeclampsia. Clin Chim Acta 2009; 4071–2: 58–61.
37. Myatt L, Clifton RG, Roberts JM et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] Maternal-Fetal Medicine Units [MFMU] Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 1196: 1234–42.
38. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
39. Stepan H, Ebert T, Schrey S et al. Preliminary report: serum levels of retinol binding protein 4 in preeclampsia. Metab Clin Exp 2009; 58: 275–7.
40. Nanda S, Nikoletakis G, Markova D et al. Maternal serum retinol-binding protein-4 at 11–13 weeks' gestation in normal and pathological pregnancies. Metabolism 2013; 626: 814–9.
41. Giguere Y, Masse J, Theriault S et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG 2015; 122: 402–10.
42. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
43. Powers RW, Roberts JM, Plymire DA et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 2012; 60: 239–46.
44. Dubrovina S.O., Mutsalkhanova Iu.S., Tikidzhieva V.Iu. Poisk rannikh prognosticheskikh markerov preeklampsii. Tavricheskii mediko-biologich. vestn. 2016; 19 (2): 62–4. [in Russian]
2. Ghulmiyyah, L, Sibai, B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36: 56–9.
3. Ananth CV, Keyes KM, Wapner RJ. Preeclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ 2013; 347: f6564.
4. Yliniemi A, Nurkkala M-M, Kopman S, Korpimaki T et al. First Trimester Placental Retinol-Binding Protein 4 (RBP4) and Pregnancy-Associated Placental Protein A (PAPP-A) in the Prediction of Early-Onset Severe Preeclampsia. Metabol clinic experimental 2015; 64: 521–26.
5. Somani S, Choudhary V, Babu P, Vijayalaxmi A. To determine association of lipid profile, serum uric acid and body mass index as a marker for preeclampsia. Int J Cur Res Rev 2015; 7 (11): 53–7.
6. North RA, McCowan LM, Dekker GA et al. Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort. BMJ 2011; 342. doi:10.1136/ bmj.d1875.
7. Wu P, van den Berg C, Alfirevic Z, O’Brien S et al. Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. Int J Mol Sci 2015; 16: 23035–56.
8. Thilaganathan B, Wormald B, Zanardini C et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 1233–8.
9. Roberge S, Giguere Y, Villa P et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012; 29: 551–6 [PubMed: 22495898].
10. Akolekar R, Syngelaki A, Sarquis R et al. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 66–74.
11. Koopmans CM, Bijlenga D, Groen H et al. Induction of labour vs. expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): A multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979–88.
12. Yu CK, Khouri O, Onwudiwe N et al. Medicine Foundation Second-Trimester Screening Group. Prediction of preeclampsia by uterine artery Doppler imaging: Relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310–3.
13. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. Int J Mol Sci 2015; 16: 17952–74.
14. Anderson UD, Gram M, Thilaganathan B et al. [97-POS]: Free fetal hemoglobin and hemoglobin-scavenging proteins are predictive first and second trimester biochemical markers for preeclampsia. Pregnancy Hypertens 2015; 5: 53.
15. Small H, Currie G, Delles C. Prostasin, proteases, and preeclampsia. J Hypertens 2016; 34: 193–5.
16. Allen RE, Rogozinska E, Cleverly K et al. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 182: 194–201. doi: 10.1016/j.ejogrb.2014.09.027 PMID: 25305662.
17. Garcé́s M, Sanchez E, Cardona L, Simanca E et al. Maternal serum meteorin levels and the risk of preeclampsia. PLoS One. doi: 10.1371/journal.pone.0131013.
18. Cuckle HS. Screening for preeclampsia – Lessons from aneuploidy screening. Placent 2011; 32 (Suppl. 1): S42–S48.
19. Redman CWG, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24: 565–70.
20. Tangerå̊s L, Austdal M, Skrå̊̊stad R, Salvesen K et al. Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia. Arterioscler Thromb Vasc Biol 2015; 35: 2478–85.
21. Tsiakkas A, Duvdevani N, Wright A et al. Serum placental growth factor in the three trimesters of pregnancy: Effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 591–8.
22. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–83.
23. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor [IGF]- dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149–53.
24. Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37–45.
25. Bersinger NA, Smarason AK, Muttukrishna S et al. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin-A, activin-A and soluble E-selectin. Hypertens Pregnancy 2003; 22: 45–55.
26. Poon LC, Akolekar R, Lachmann R et al. Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010; 35: 662–70.
27. Sibai BM, Koch MA, Freire S et al. Serum inhibin-A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: Are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008; 199: 268e1–e9.
28. Shi Z, Xu W, Loechel F et al. ADAM 12, a disintegrinmetalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574–80.
29. Loechel F, Fox JW, Murphy G et al. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511–5.
30. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212–6.
31. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod 2007; 13: 189–95.
32. Thilaganathan B, Ralph E, Papageorghiou AT et al. Raised maternal serum cystatin C: An early pregnancy marker for preeclampsia. Reprod Sci 2009; 16: 788–93.
33. Metcalfe A, Langlois S, Macfarlane J et al. Prediction of obstetrical risk using maternal serum markers and clinical risk factors. Prenat Diagn 2013; 2: 172–9.
34. Vaisbuch E, Romero R, Mazaki-Tovi S et al. Retinol binding protein 4 – a novel association with early-onset preeclampsia. J Perinat Med 2010; 382: 129–39.
35. Alkharfy KM, Al-Daghri NM, Vanhoutte PM et al. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS One 2012; 710: e48612.
36. Shangguan XI, Liu F, Wang H et al. Alterations in serum adipocyte fatty acid binding protein and retinol binding protein-4 in normal pregnancy and preeclampsia. Clin Chim Acta 2009; 4071–2: 58–61.
37. Myatt L, Clifton RG, Roberts JM et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] Maternal-Fetal Medicine Units [MFMU] Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 1196: 1234–42.
38. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
39. Stepan H, Ebert T, Schrey S et al. Preliminary report: serum levels of retinol binding protein 4 in preeclampsia. Metab Clin Exp 2009; 58: 275–7.
40. Nanda S, Nikoletakis G, Markova D et al. Maternal serum retinol-binding protein-4 at 11–13 weeks' gestation in normal and pathological pregnancies. Metabolism 2013; 626: 814–9.
41. Giguere Y, Masse J, Theriault S et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG 2015; 122: 402–10.
42. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
43. Powers RW, Roberts JM, Plymire DA et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 2012; 60: 239–46.
44. Дубровина С.О., Муцалханова Ю.С., Тикиджиева В.Ю. Поиск ранних прогностических маркеров преэклампсии. Таврический медико-биологич. вестн. 2016; 19 (2): 62–4. / Dubrovina S.O., Mutsalkhanova Iu.S., Tikidzhieva V.Iu. Poisk rannikh prognosticheskikh markerov preeklampsii. Tavricheskii mediko-biologich. vestn. 2016; 19 (2): 62–4. [in Russian]
________________________________________________
2. Ghulmiyyah, L, Sibai, B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36: 56–9.
3. Ananth CV, Keyes KM, Wapner RJ. Preeclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ 2013; 347: f6564.
4. Yliniemi A, Nurkkala M-M, Kopman S, Korpimaki T et al. First Trimester Placental Retinol-Binding Protein 4 (RBP4) and Pregnancy-Associated Placental Protein A (PAPP-A) in the Prediction of Early-Onset Severe Preeclampsia. Metabol clinic experimental 2015; 64: 521–26.
5. Somani S, Choudhary V, Babu P, Vijayalaxmi A. To determine association of lipid profile, serum uric acid and body mass index as a marker for preeclampsia. Int J Cur Res Rev 2015; 7 (11): 53–7.
6. North RA, McCowan LM, Dekker GA et al. Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort. BMJ 2011; 342. doi:10.1136/ bmj.d1875.
7. Wu P, van den Berg C, Alfirevic Z, O’Brien S et al. Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis. Int J Mol Sci 2015; 16: 23035–56.
8. Thilaganathan B, Wormald B, Zanardini C et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 1233–8.
9. Roberge S, Giguere Y, Villa P et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012; 29: 551–6 [PubMed: 22495898].
10. Akolekar R, Syngelaki A, Sarquis R et al. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 66–74.
11. Koopmans CM, Bijlenga D, Groen H et al. Induction of labour vs. expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): A multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979–88.
12. Yu CK, Khouri O, Onwudiwe N et al. Medicine Foundation Second-Trimester Screening Group. Prediction of preeclampsia by uterine artery Doppler imaging: Relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310–3.
13. Park HJ, Shim SS, Cha DH. Combined Screening for Early Detection of Pre-Eclampsia. Int J Mol Sci 2015; 16: 17952–74.
14. Anderson UD, Gram M, Thilaganathan B et al. [97-POS]: Free fetal hemoglobin and hemoglobin-scavenging proteins are predictive first and second trimester biochemical markers for preeclampsia. Pregnancy Hypertens 2015; 5: 53.
15. Small H, Currie G, Delles C. Prostasin, proteases, and preeclampsia. J Hypertens 2016; 34: 193–5.
16. Allen RE, Rogozinska E, Cleverly K et al. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 182: 194–201. doi: 10.1016/j.ejogrb.2014.09.027 PMID: 25305662.
17. Garcé́s M, Sanchez E, Cardona L, Simanca E et al. Maternal serum meteorin levels and the risk of preeclampsia. PLoS One. doi: 10.1371/journal.pone.0131013.
18. Cuckle HS. Screening for preeclampsia – Lessons from aneuploidy screening. Placent 2011; 32 (Suppl. 1): S42–S48.
19. Redman CWG, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24: 565–70.
20. Tangerå̊s L, Austdal M, Skrå̊̊stad R, Salvesen K et al. Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia. Arterioscler Thromb Vasc Biol 2015; 35: 2478–85.
21. Tsiakkas A, Duvdevani N, Wright A et al. Serum placental growth factor in the three trimesters of pregnancy: Effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 591–8.
22. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–83.
23. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor [IGF]- dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149–53.
24. Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37–45.
25. Bersinger NA, Smarason AK, Muttukrishna S et al. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin-A, activin-A and soluble E-selectin. Hypertens Pregnancy 2003; 22: 45–55.
26. Poon LC, Akolekar R, Lachmann R et al. Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010; 35: 662–70.
27. Sibai BM, Koch MA, Freire S et al. Serum inhibin-A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: Are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008; 199: 268e1–e9.
28. Shi Z, Xu W, Loechel F et al. ADAM 12, a disintegrinmetalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574–80.
29. Loechel F, Fox JW, Murphy G et al. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511–5.
30. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212–6.
31. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod 2007; 13: 189–95.
32. Thilaganathan B, Ralph E, Papageorghiou AT et al. Raised maternal serum cystatin C: An early pregnancy marker for preeclampsia. Reprod Sci 2009; 16: 788–93.
33. Metcalfe A, Langlois S, Macfarlane J et al. Prediction of obstetrical risk using maternal serum markers and clinical risk factors. Prenat Diagn 2013; 2: 172–9.
34. Vaisbuch E, Romero R, Mazaki-Tovi S et al. Retinol binding protein 4 – a novel association with early-onset preeclampsia. J Perinat Med 2010; 382: 129–39.
35. Alkharfy KM, Al-Daghri NM, Vanhoutte PM et al. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS One 2012; 710: e48612.
36. Shangguan XI, Liu F, Wang H et al. Alterations in serum adipocyte fatty acid binding protein and retinol binding protein-4 in normal pregnancy and preeclampsia. Clin Chim Acta 2009; 4071–2: 58–61.
37. Myatt L, Clifton RG, Roberts JM et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] Maternal-Fetal Medicine Units [MFMU] Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 1196: 1234–42.
38. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
39. Stepan H, Ebert T, Schrey S et al. Preliminary report: serum levels of retinol binding protein 4 in preeclampsia. Metab Clin Exp 2009; 58: 275–7.
40. Nanda S, Nikoletakis G, Markova D et al. Maternal serum retinol-binding protein-4 at 11–13 weeks' gestation in normal and pathological pregnancies. Metabolism 2013; 626: 814–9.
41. Giguere Y, Masse J, Theriault S et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG 2015; 122: 402–10.
42. Poon LC, Maiz N, Valencia C et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23–33.
43. Powers RW, Roberts JM, Plymire DA et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 2012; 60: 239–46.
44. Dubrovina S.O., Mutsalkhanova Iu.S., Tikidzhieva V.Iu. Poisk rannikh prognosticheskikh markerov preeklampsii. Tavricheskii mediko-biologich. vestn. 2016; 19 (2): 62–4. [in Russian]
Авторы
С.О.Дубровина*1, 2, Ю.С.Муцалханова1
1. ГБОУ ВПО Ростовский государственный медицинский университет Минздрава России. 344022, Россия, Ростов-на-Дону, Нахичеванский пер., д. 29;
2. ФГБУ Ростовский научно-исследовательский институт акушерства и педиатрии Минздрава России. 344012, Россия, Ростов-на-Дону, ул. Мечникова, д. 43
*s.dubrovina@gmail.com
1. Rostov State Medical University of the Ministry of Health of the Russian Federation. 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29;
2. Rostov-on-Don Scientific Research Institute of Obstetrics and Pediatrics of the Ministry of Health the Russian Federation. 344012, Russian Federation, Rostov-on-don, ul. Mechnikova, d. 43
*s.dubrovina@gmail.com
1. ГБОУ ВПО Ростовский государственный медицинский университет Минздрава России. 344022, Россия, Ростов-на-Дону, Нахичеванский пер., д. 29;
2. ФГБУ Ростовский научно-исследовательский институт акушерства и педиатрии Минздрава России. 344012, Россия, Ростов-на-Дону, ул. Мечникова, д. 43
*s.dubrovina@gmail.com
________________________________________________
1. Rostov State Medical University of the Ministry of Health of the Russian Federation. 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29;
2. Rostov-on-Don Scientific Research Institute of Obstetrics and Pediatrics of the Ministry of Health the Russian Federation. 344012, Russian Federation, Rostov-on-don, ul. Mechnikova, d. 43
*s.dubrovina@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.